Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Agomab said open-label extension data from its Phase 2a STENOVA study of ontunisertib will be presented at UEG Week 2026. The company also plans a scientific symposium on fibro-inflammation and said the results support starting its Phase 2b NOV-ERA study.
Agomab plans to present STENOVA open-label extension data of ontunisertib at UEG Week 2026 and host a scientific symposium on fibro-inflammation.